N-(tert-butyl)-2-oxo-4-phen ylbutanamide | 31334-65-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-(tert-butyl)-2-oxo-4-phen ylbutanamide
• 英文别名: N-tert-butyl-2-oxo-4-phenylbutanamide
• CAS: 31334-65-3
• 化学式: C₁₄H₁₉NO₂
• 分子量: 233.31
• InChiKey: DLZYXTWQKSEJMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-苯基乙基-1-硼酸频哪醇酯 在 manganese(III) triacetate dihydrate 作用下， 以 甲醇 、 水 、 1,2-二氯乙烷 为溶剂， 20.0~60.0 ℃ 、6.0 MPa 条件下， 反应 28.0h， 生成 N-(tert-butyl)-2-oxo-4-phen ylbutanamide
  参考文献：
  名称：

  锰 (III) 促进苯胺双羰基化合成 α-酮酰胺

  摘要：

  在双羰基化中使用苯胺作为亲核试剂是一个长期的挑战。在本次交流中，已经开发了一种 Mn(III) 促进的烷基硼酸盐或 Hantzsch 酯与苯胺的双羰基化，用于合成 α-酮酰胺。通过使用容易获得的烷基三氟硼酸钾或 Hantzsch 酯作为起始材料，并以廉价且无毒的 Mn(OAc) 3  · 2H 2 O 作为促进剂，以中等至良好的收率合成了范围广泛的烷基α-酮酰胺衍生物。优良的选择性。

  DOI：

  10.1002/adsc.202101233

文献信息

• Iridium/f-Amphox-Catalyzed Asymmetric Hydrogenation of Styrylglyoxylamides
  作者：Jialin Wen、Xumu Zhang、Simin Wang、Yuena Yu

  DOI：10.1055/s-0037-1609623

  日期：2018.10

  We report an iridium-catalyzed asymmetric hydrogenation reaction for the preparation of chiral homophenylalanine derivatives. Catalyzed by an iridium/f-amphox complex, the asymmetric hydrogenation of styrylglyoxylamides was conducted smoothly with turnover numbers of up to 10,000 and up to 98% ee. This method was successfully applied in a synthesis of a fragment of benazepril, a drug used for the treatment

  我们报告了用于制备手性高苯丙氨酸衍生物的铱催化不对称氢化反应。在铱/f-amphox 络合物的催化下，苯乙烯基乙醛酰胺的不对称氢化顺利进行，转化率高达 10,000，ee 高达 98%。该方法已成功应用于苯那普利片段的合成，这是一种用于治疗高血压的药物。
• A Nonoxidative Passerini Pathway to α-Ketoamides
  作者：Raoudha Abderrahim、Laurent El Kaïm、Abdelbari Abdessalem

  DOI：10.1055/s-0035-1560632

  日期：——

  The Passerini adducts of cinnamaldehyde derivatives may be efficiently converted into alpha-ketoamides when heated with a base under microwave conditions.
• Synthesis and biological evaluation of α-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture
  作者：Christian Steuer、Christian Gege、Wolfgang Fischl、Karl H. Heinonen、Ralf Bartenschlager、Christian D. Klein

  DOI：10.1016/j.bmc.2011.05.015

  日期：2011.7

  The development of small molecule inhibitors of the viral protease is of considerable interest for the treatment of emergent flaviviral diseases such as Dengue or West Nile fever. Until today little progress has been made in finding drug-like compounds that inhibit the protease and provide a starting point for lead optimization. We describe here the initial steps of a drug discovery effort that focused on the styryl pharmacophore, combined with a ketoamide function to serve as electrophilic trap for the catalytic serine. This resulted in a fragment-like lead compound with reasonable target affinity and good ligand efficiency, which was extensively modified to explore structure-activity relationships. Selected compounds were cross-tested against the West Nile virus protease and thrombin, indicating that selectivity for one or more flaviviral proteases can be achieved. Finally, the antiviral activity of several protease inhibitors was confirmed in a cell-culture model of Dengue virus replication. The SAR presented here may serve as starting point for further drug discovery efforts with the aim of targeting flaviviral proteases. (C) 2011 Elsevier Ltd. All rights reserved.